Clinical Trials Logo

Ebola clinical trials

View clinical trials related to Ebola.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05301504 Active, not recruiting - Ebola Clinical Trials

A Study in Tanzania of a New Vaccine Against Two Types of Ebola

Start date: March 30, 2022
Phase: Phase 1
Study type: Interventional

An open label, first in human, non-randomised, dose escalation, single centre, phase Ib clinical trial

NCT ID: NCT05284097 Active, not recruiting - Infections Clinical Trials

Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study

Start date: September 19, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, study evaluating the safety and immunogenicity of the 2-dose vaccination regimen, Ad26.ZEBOV, MVA-BN-Filo, in adults and children originally enrolled in the control arm of the EBOVAC-Salone study

NCT ID: NCT03031912 Active, not recruiting - Ebola Clinical Trials

African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVĪ”G-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.